Stockscreener 앱 받기
12.21
1.53%
-0.19
전일 마감가:
$12.40
열려 있는:
$12.2
하루 거래량:
125.77K
Relative Volume:
0.32
시가총액:
$401.19M
수익:
$2.07M
순이익/손실:
$-47.68M
주가수익비율:
-4.3298
EPS:
-2.82
순현금흐름:
$-31.31M
1주 성능:
+1.75%
1개월 성능:
+10.90%
6개월 성능:
+12.02%
1년 성능:
+119.60%
1일 변동 폭
$12.11
$12.32
1주일 범위
$11.82
$12.49
52주 변동 폭
$5.30
$16.97
Delcath Systems Inc Stock (DCTH) Company Profile
명칭
Delcath Systems Inc
전화
(518) 743-8892
주소
566 QUEENSBURY AVENUE, QUEENSBURY, NY
DCTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
12.22 | 401.19M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
132.26 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.53 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.50 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.38 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.37 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Craig Hallum | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2022-07-26 | 재개 | Canaccord Genuity | Buy |
| 2021-12-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Canaccord Genuity | Buy |
| 2021-01-05 | 개시 | BTIG Research | Buy |
| 2020-06-01 | 개시 | Laidlaw | Buy |
모두보기
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Repligen (RGEN) and CareDx (CDNA) - The Globe and Mail
FDA clears Delcath’s Phase 2 trial for breast cancer treatment By Investing.com - Investing.com South Africa
FDA clears Delcath’s Phase 2 trial for breast cancer treatment - Investing.com Australia
Delcath Systems Gets FDA Clearance to Start Phase 2 Trial of Hepzato for Metastatic Breast Cancer - marketscreener.com
Delcath Systems (DCTH) Cleared by FDA to Start Phase 2 Trial for Hepzato | DCTH Stock News - GuruFocus
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
FDA Green Lights Delcath's Breakthrough Liver Cancer Tech Expansion into Breast Cancer Market - Stock Titan
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer - The Joplin Globe
Geode Capital Management LLC Buys 37,056 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
Financial Metrics Unveiled: Delcath Systems Inc (DCTH)’s Key Ratios in the Spotlight - DWinneX
Delcath Systems Inc (DCTH) shows promising results - uspostnews.com
Liver Cancer Treatment Leader Delcath Systems to Report Q1 2025 Earnings May 8 - Stock Titan
(DCTH) Proactive Strategies - news.stocktradersdaily.com
Moffitt-Led International Study Finds New Drug Delivery System Effective Against Rare Eye Cancer - Central Florida Health News
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock? - Nasdaq
Delcath Systems Announces Publication of Comparative Analysis fr - GuruFocus
Clinical Data: Delcath's Melanoma Treatment Achieves 175% Better Survival Than Standard Care - Stock Titan
How To Trade (DCTH) - news.stocktradersdaily.com
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Hospitals Experience FOMO In Adopting Delcath’s PHP Treatment (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Is Expected To Breakeven In The Near Future - simplywall.st
Charles Schwab Investment Management Inc. Invests $156,000 in Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
5,470 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Quantbot Technologies LP - Defense World
Delcath Systems (NASDAQ:DCTH) and West Pharmaceutical Services (NYSE:WST) Critical Survey - Defense World
Beta Bionics Announces Board Appointment of Gerard Michel - The Manila Times
Beta Bionics appoints new board member from Delcath Systems By Investing.com - Investing.com South Africa
Beta Bionics appoints new board member from Delcath Systems - Investing.com India
Jim Cramer Blesses Delcath Systems (DCTH): ‘You’re Not Early, But It’s a Win’ - MSN
Jim Cramer Discussed These 6 Stocks Recently - Insider Monkey
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High? - MSN
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference - Lelezard
Liver Cancer Treatment Breakthrough? Delcath to Reveal Latest Advances at Major Oncology Conference - Stock Titan
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2024 Earnings Call Transcript - MSN
Delcath Systems awards stock options to new employees By Investing.com - Investing.com Australia
Delcath Systems awards stock options to new employees - Investing.com India
Delcath Systems Strengthens Workforce: 264,000 Stock Options Granted to New Strategic Hires - StockTitan
Delcath Systems Reports Strong 2024 Financial Growth - TipRanks
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For - Simply Wall St
Delcath Systems’ Earnings Call Highlights Strong Growth and Strategic Expansion - TipRanks
HC Wainwright Estimates Delcath Systems FY2029 Earnings - Defense World
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $24.00 - Defense World
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates - MSN
Earnings Beat: Delcath Systems, Inc. (NASDAQ:DCTH) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Private Advisor Group LLC Acquires New Position in Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
Positive Outlook for Delcath Systems: Promising Growth and Strategic Expansion Drive Buy Rating - TipRanks
Delcath stock price target raised to $24 by H.C. Wainwright - Investing.com India
Delcath Systems Inc (DCTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.27%
0.14%
자본화:
|
볼륨(24시간):